Innovent Advances First-in-Class IBI363 to Pivotal Trials for Immunotherapy-Resistant Lung Cancer
核心洞察
Innovent Biologics (搜索) will present new proof-of-concept data for IBI363, a first-in-class PD-1 (搜索)/IL-2α (搜索)-biased bispecific fusion protein, at the 2026 ASCO Annual Meeting.
The company is advancing IBI363 into multi-regional clinical trial pivotal development for immunotherapy-resistant non-small cell lung cancer based on robust proof-of-concept data.
IBI363 shows promise in both immunotherapy-resistant and first-line NSCLC settings, with a Phase III study (MarsLight-11) comparing it to docetaxel in squamous NSCLC patients.
Innovent Biologics (搜索) announced it will present new clinical data for its first-in-class bispecific fusion protein IBI363 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, marking a significant milestone as the company advances the therapy into pivotal development for immunotherapy-resistant non-small cell lung cancer (NSCLC).
The Chinese biopharmaceutical company will showcase proof-of-concept data for IBI363, a PD-1 (搜索)/IL-2α (搜索)-biased bispecific fusion protein, across both immunotherapy-resistant and first-line NSCLC settings during the meeting scheduled for May 29 to June 2, 2026, in Chicago.
Pivotal Development for Unmet Medical Need
Dr. Hui Zhou, Chief R&D Officer (Oncology) of Innovent, emphasized the clinical significance of the advancement: "With robust PoC data for IO-resistant NSCLC now in hand, we are moving IBI363 into MRCT pivotal development, an important step toward tackling a major global unmet medical need."
The company's decision to advance IBI363 into multi-regional clinical trial (MRCT) pivotal development reflects confidence in the therapy's potential to address immunotherapy resistance, a significant challenge in current lung cancer treatment.
Clinical Data Presentations
Three key presentations will highlight IBI363's clinical progress:
First-Line Treatment Data: Dr. Haiyan Tu from Guangdong Provincial People's Hospital will present results from a study evaluating IBI363 (also known as TAK-928) plus chemotherapy as first-line treatment for advanced NSCLC.
Immunotherapy-Resistant Population: Updated Phase I results for IBI363 in patients with advanced immunotherapy-resistant NSCLC will be presented by Dr. Jianya Zhou from the First Affiliated Hospital of Zhejiang University School of Medicine.
Phase III Trial Design: The randomized Phase III MarsLight-11 study design, comparing IBI363 versus docetaxel in patients with squamous NSCLC after prior chemotherapy and immunotherapy, will be presented by Dr. Roy S. Herbst from Yale School of Medicine.
Dose Optimization Progress
Zhou noted encouraging results from dose optimization studies in first-line NSCLC, stating the company looks forward to "continued maturation of PoC full data to inform our next steps." This suggests ongoing refinement of the therapeutic approach as the program advances.
Comprehensive TYVYT Portfolio
Beyond IBI363, Innovent will present data from nine studies of TYVYT (sintilimab injection), its PD-1 (搜索) antibody, across multiple cancer types. These presentations span hepatocellular carcinoma, colorectal cancer, rectal cancer, laryngeal cancer, esophageal squamous cell carcinoma, epithelioid sarcoma, and malignant pleural mesothelioma.
Notable TYVYT studies include the SCIENCE trial in esophageal squamous cell carcinoma, which will be featured as a late-breaking abstract, and the CLEAR-2 study evaluating adjuvant sintilimab plus bevacizumab following curative resection of spontaneously ruptured hepatocellular carcinoma.
Company Portfolio and Partnerships
Innovent, founded in 2011, has established itself as a leading biopharmaceutical company with 18 products currently in the market, 5 assets in Phase III or pivotal clinical trials, and 14 molecules in early clinical development. The company maintains partnerships with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda (搜索), Sanofi, Incyte, LG Chem (搜索), and MD Anderson Cancer Center.
The advancement of IBI363 represents a significant step in addressing immunotherapy resistance in lung cancer, potentially offering new treatment options for patients who have exhausted current therapeutic approaches.